KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

AbbVie (ABBV) EBT (2016 - 2026)

AbbVie has reported EBT over the past 14 years, most recently at $2.7 billion for Q4 2025.

  • Quarterly EBT rose 217.58% to $2.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 billion through Dec 2025, up 77.53% year-over-year, with the annual reading at $6.6 billion for FY2025, 77.53% up from the prior year.
  • EBT was $2.7 billion for Q4 2025 at AbbVie, up from $714.0 million in the prior quarter.
  • Over five years, EBT peaked at $4.9 billion in Q1 2022 and troughed at -$2.3 billion in Q4 2024.
  • The 5-year median for EBT is $2.0 billion (2023), against an average of $2.2 billion.
  • Year-over-year, EBT surged 383.41% in 2021 and then crashed 287.21% in 2024.
  • A 5-year view of EBT shows it stood at $4.3 billion in 2021, then crashed by 30.58% to $3.0 billion in 2022, then crashed by 59.12% to $1.2 billion in 2023, then crashed by 287.21% to -$2.3 billion in 2024, then soared by 217.58% to $2.7 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's EBT are $2.7 billion (Q4 2025), $714.0 million (Q3 2025), and $1.6 billion (Q2 2025).